Pfizer, Haleon
Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon -- Update
Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital. The pharmaceutical giant said Monday that the price per share will be determined by way of an accelerated bookbuilding process to institutional investors.
On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $29.09 which represents a slight increase of $0.12 or 0.41% from the prior close of $28.97. The stock opened at $29.02 and ...
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
4d
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and ...
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback